

# Methazolamide

Cat. No.: HY-B0553 CAS No.: 554-57-4 Molecular Formula:  $C_5H_8N_4O_3S_2$ Molecular Weight: 236.27

Target: Carbonic Anhydrase

Pathway: Metabolic Enzyme/Protease

Storage: 4°C, protect from light

\* In solvent: -80°C, 1 year; -20°C, 6 months (protect from light)

**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO:  $\geq 50 \text{ mg/mL} (211.62 \text{ mM})$ 

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	4.2324 mL	21.1622 mL	42.3245 mL
	5 mM	0.8465 mL	4.2324 mL	8.4649 mL
	10 mM	0.4232 mL	2.1162 mL	4.2324 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a K <sub>i</sub> of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	CA ⊠

# **CUSTOMER VALIDATION**

- Cell Metab. 2022 Feb 7;34(3):424-440.e7.
- Research Square Print. November 28th, 2022.

See more customer validations on www.MedChemExpress.com

### **REFERENCES**

[1]. Yang F, et al. HLA-B\*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharmacogenomics J. 2016;16(1):83-87.

[2]. Abbate F, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors. J Enzyme Inhib Med Chem. 2003;18(4):303-308.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA